

March 16, 2021



VistaGen Therapeutics to Participate in Upcoming Investor Conferences in March

SOUTH SAN FRANCISCO, Calif., March 16, 2021 (GLOBE NEWSWIRE) -- [VistaGen Therapeutics](#) (NASDAQ: VTGN), a biopharmaceutical company committed to developing and commercializing a new generation of medicines with the potential to go beyond the current standard of care for anxiety, depression and other central nervous system (CNS) disorders, today announced that [Shawn Singh, VistaGen's Chief Executive Officer](#), will participate in the following investor conferences in March:

Maxim Group and M-Vest's Inaugural Emerging Growth Virtual Conference

Dates: March 17th – 19th

Format: Corporate Presentation & One-on-One Fireside Chat

Date: Friday, March 19th at 1:00 p.m. ET

Format: Fireside Chat with Jason McCarthy, Research Analyst

Website: To attend the virtual conference, register [here](#)
<https://www.m-vest.com/events/2021-emerging-growth-virtual-conference>

Benzinga Biotech Small Cap Conference

Date: Thursday, March 25th at 10:05 a.m. ET

Format: Corporate Presentation

Website: To attend the virtual conference, register [here](#)
<https://events.benzinga.com/registration-page16068526119171607978331877>

For more information regarding the conferences, please visit the sponsor conference websites.

About VistaGen

VistaGen Therapeutics is a biopharmaceutical company committed to developing and commercializing innovative medicines with the potential to go beyond the current standard of care for anxiety, depression, and other CNS disorders. Each of VistaGen's three drug candidates has a differentiated potential mechanism of action, has been well-tolerated in all clinical studies to date and has therapeutic potential in multiple CNS markets. For more information, please visit www.vistagen.com and connect with VistaGen on Twitter, LinkedIn, and Facebook.

Company Contact

Mark A. McPartland

VistaGen Therapeutics, Inc.

Phone: +1 (650) 577-3600

Email: IR@vistagen.com



VistaGen®
Therapeutics

Source: VistaGen Therapeutics, Inc.